L152-0631 Screening compound: 5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H,5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxamide

L152-0631 Screening compound: 5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H,5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxamide
L152-0631 Screening compound: 5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H,5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L152-0631
5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H,5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L152-0631

Molecular Formula

C26H22ClN5O3 (C26 H22 ClN5 O3)

Compound Name

5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H,5H-[1,2,4]triazolo[1,5-a]quinoxaline-2-carboxamide

IUPAC name

5-[(3-chlorophenyl)methyl]-N-(2-methoxy-5-methylphenyl)-7-methyl-4-oxo-4H5H-[124]triazolo[15-a]quinoxaline-2-carboxamide

SMILES

Cc(cc1)cc(NC(c(nc23)nn2-c(ccc(C)c2)c2N(Cc2cccc(Cl)c2)C3=O)=O)c1OC

InChI

InChI=1S/C26H22ClN5O3/c1-15-8-10-22(35-3)19(11-15)28-25(33)23-29-24-26(34)31(14-17-5-4-6-18(27)13-17)21-12-16(2)7-9-20(21)32(24)30-23/h4-13H,14H2,1-3H3,(H,28,33)

InChI Key

NUQZQOKQAVTFFW-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27234724

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

487.95

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

5.074

Distribution Coefficient, logD

5.072

Water Solubility, LogSw

-5.15

Polar Surface Area

68.647

Acid Dissociation Constant (pKa)

9.87

Base Dissociation Constant (pKb)

-4.30

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

15.40

L152-0631 in Drug Discovery

Included in Screening Libraries

Antimitotic Tubulin Library (17355 compounds)

Antiviral HBV Library (10007 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

Protein Kinases Inhibitors Library (36801 compounds)

Adenosine Receptors Targeted Library (19896 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Antiviral
  • Infections
  • Immune system
  • Hemic and lymphatic
  • Cardiovascular
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Nervous system
  • Hemic and lymphatic
  • Cardiovascular
  • Cancer
  • Digestive system
  • Respiratory tract
  • Nervous system
  • Eye
  • Cardiovascular
Targets:
  • Kinases
  • GPCR
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with L152-0631 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L152-0631?
Check Price and Availability of L152-0631, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L152-0631 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L152-0631
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L152-0631
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L152-0631 available by request